Exclusive Summary

• Superior Safety and Compliance Profile: As a long-acting GLP-1 RA, UB011 demonstrates exceptionally low gastrointestinal adverse events (8.0% nausea rate) and creates a unique selling point with its "No-Need-for-Titration" dosing regimen.
• De-risked Clinical Development: Phase 3 in China is completed (N~1000), and US Phase 2 (in combo with Metformin) is finalized with FDA scientific advice (Type C Meeting) secured.
• Rapid Onset and Systemic Benefits: Delivers rapid glycemic control (nearly 1% HbA1c reduction in the first 4 weeks) along with clinically significant reductions in blood pressure, lipids, and insulin resistance.
• Strategic Global Partnership Opportunity: Offering Ex-China co-development or licensing opportunities for a mature asset that addresses the high discontinuation rates of current GLP-1 therapies due to tolerability issues.

Asset Materials

Contact Us for Full Materials